Trial | NCT03244072  Report issue

Title

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Not yet recruiting

  • Study Participants

    60000
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.
Study Started
Jun 01
2024
Anticipated
Primary Completion
Oct 31
2025
Anticipated
Study Completion
Oct 31
2025
Anticipated
Last Update
Jul 27
2023

Drug Moxifloxacin

Intracameral injection

  • Other names: active

Drug Placebo

intracameral injection

  • Other names: sham

Treatment group Active Comparator

Intracameral injection of moxifloxacin solution after cataract surgery

Placebo group Placebo Comparator

Intracameral injection of placebo after cataract surgery

Criteria 

Inclusion Criteria:

visually significant cataracts

Exclusion Criteria:

allergy to fluoroquinolones, cobalamin (B12)
No Results Posted